Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients

Frontiers in Pharmacology
Zulfan ZazuliAnke-Hilse Maitland-van der Zee

Abstract

Antineoplastic effect of cisplatin, the first line treatment in non-small cell lung cancer (NSCLC), is hindered by its nephrotoxicity and myelotoxicity. Both low-dose and high-dose regimens are used in the management of NSCLC. The aim of this study is to assess the risk on myelotoxicity and nephrotoxicity from the daily low-dose cisplatin (DLD) treatment as compared to cyclic high-dose cisplatin (CHD). A retrospective cohort study was conducted. NSCLC patients treated with cisplatin between 2011 and 2018 in the Amsterdam UMC or Antoni van Leeuwenhoek cancer hospital were studied. Myelotoxicity and nephrotoxicity were defined based on common terminology criteria (CTCAE v4.03) and categorized as ≥grade 1 and ≥grade 2. Modified Poisson regression and Cox proportional hazards model were used to estimate relative risks and cumulative hazard respectively. Of the 115 NSCLC patients receiving DLD (N=62) and CHD (N=53), 60% had ≥grade 1 anemia, 33.9% leukopenia, 31.3% neutropenia, 27.8% thrombocytopenia, 32.2% acute nephrotoxicity with combined definition (Cr-electrolyte nephrotoxicity), and 58.3% chronic nephrotoxicity. The DLD group was older, had an earlier cancer stage, had more comorbidities, and had higher baseline albumin levels....Continue Reading

References

Jan 1, 1990·Cancer Chemotherapy and Pharmacology·G MilanoJ L Lagrange
Oct 1, 1988·Toxicology Letters·F F FarrisF G King
Jul 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A L Schuster-UitterhoeveH Bartelink
Aug 6, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·B BiedermannM Pless
Jun 5, 2003·Expert Opinion on Pharmacotherapy·Jörg Thomas Hartmann, Hans-Peter Lipp
Mar 23, 2004·American Journal of Epidemiology·Guangyong Zou
May 14, 2005·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jose BelderbosJoos Lebesque
Nov 7, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·José BelderbosUNKNOWN EORTC LCG and RT Group
Feb 15, 2008·Kidney International·N Pabla, Z Dong
Jan 14, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MoreauM Paesmans
Nov 4, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Dale HardyXianglin L Du
Jul 5, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Ingrid KappersCaro C E Koning
Sep 24, 2011·World Journal of Gastroenterology : WJG·Hyung Hwan MoonSang Ho Lee
Dec 12, 2012·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jasper NijkampJan-Jakob Sonke
May 8, 2013·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Wilma UyterlindeMichel van den Heuvel
Jul 19, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J VansteenkisteUNKNOWN ESMO Guidelines Working Group
Oct 1, 2013·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Chun ChenJosé Belderbos
Jan 22, 2014·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Wilma UyterlindeMichel van den Heuvel
Mar 29, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B BesseUNKNOWN ESMO
Dec 3, 2014·Genomics, Proteomics & Bioinformatics·Maimon C RoseR Stephanie Huang
Jan 8, 2016·American Journal of Physiology. Renal Physiology·Cierra N SharpLeah J Siskind
Feb 18, 2016·Cancer Chemotherapy and Pharmacology·Shahana Dilruba, Ganna V Kalayda
Feb 24, 2016·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Judi N A van DiessenJan-Jakob Sonke
Feb 26, 2016·Journal of Pediatric Hematology/oncology·Osvaldo D Castelán-MartínezRodolfo Rivas-Ruiz
Jan 17, 2017·International Journal of Epidemiology·Johannes TextorGeorge Th Ellison
Apr 20, 2017·International Journal of Urology : Official Journal of the Japanese Urological Association·Masatomo NishikawaMasato Fujisawa
Oct 7, 2017·The Journal of Obstetrics and Gynaecology Research·Yoshihiro YamamotoAkihiko Wakatsuki
Oct 16, 2018·Frontiers in Pharmacology·Zulfan ZazuliAnke-Hilse Maitland-van der Zee

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Zhongguo yao li xue bao = Acta pharmacologica Sinica
L W WangW C Li
Journal of UOEH
R Safirstein, J Wiston
Cancer Chemotherapy and Pharmacology
G Daugaard, U Abildgaard
Developments in Toxicology and Environmental Science
J NakadaH Endou
© 2021 Meta ULC. All rights reserved